A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer

Clinical Breast Cancer

Volumn 9, Issue 3, 2009, Pages 161-165

  George, Joseph ^a   Dharanipragada, Kadambari ^a   Krishnamachari, Srinivasan ^a   Chandrasekaran, Adithan ^a   Sam, Soya Sisy ^a   Sunder, Elangovan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

3435C > T; Chemoresistance; Exon 26; T allele

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; CAF PROTOCOL; GLYCOPROTEIN P; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SUSCEPTIBILITY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EXON; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MDR1 GENE; MULTIPLE CYCLE TREATMENT; PREVALENCE; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR GENE; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70350787162     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.026     Document Type: Article

References (20)

1. Lee W, Lockhart AC, Kim RB, et al. Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. Oncologist 2005;10:104-11.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
3. Ueda K, Clark D P, Chen CJ, et al. The human multidrug resistance (MDR1) gene.cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-8.
4. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.
5. Siegsmund M, Brinkmann U, Schaffeler E, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumours. J Am Soc Nephrol 2002;13:1847-54.
6. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-62.
7. Von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V 13 allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:1048-52.
8. Calado RT, Falcao R P, Garcia AB, et al. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002;87:564-8.
9. Sam SS, Thomas V, Sivagnanama K, et al. ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenet Genomics 2007;17:861-6.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
11. Stavrovskaya A. Cellular Mechanisms of Multidrug Resistance of Tumor Cells. Biochemistry (Moscow) 2000;65: 95-106. Translated from Biokhimiya 2000;65:112-26.
12. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
13. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; (30) :96-102.
14. Van der Hage J, Van de Velde CJ, Julien J P, et al. Preoperative Chemotherapy in Primary Operable Breast Cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224-37.
15. Ramasamy K, Sisy SS, Chandrasekaran A. Allele and genotype frequency of MDR1 C3435T in Tamilian population. Drug Metab Pharmacokinet 2006;21:506-8.
16. Turgut S, Yaren A, Kursunluoglu R, et al. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007;38:539-44.
17. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003;22:1117-21.
18. Rodrigues F F, Santos RE, Melo MB, et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 2008;7:177-83.
19. Kurzawski M, Drozdzik M, Suchy J, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005;61:389-94.
20. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33.